{"drugs":["Mercaptopurine","Purinethol","Purixan"],"mono":{"0":{"id":"368950-s-0","title":"Generic Names","mono":"Mercaptopurine"},"1":{"id":"368950-s-1","title":"Dosing and Indications","sub":[{"id":"368950-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute lymphoid leukemia, Maintenance therapy, as part of combination chemotherapy:<\/b> 1.5 to 2.5 mg\/kg\/day ORALLY as single dose  (50 to 75 mg\/m(2)\/day)<\/li><li><b>Chronic myeloid leukemia:<\/b> optimal dosing and timing not yet defined<\/li><li><b>Crohn's disease:<\/b> 1.5 mg\/kg\/day ORALLY; adjust dose to maintain white blood cell count above 4,500 and platelet count above 100,000<\/li><\/ul>"},{"id":"368950-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Acute lymphoid leukemia, Maintenance therapy, as part of combination chemotherapy:<\/b> 1.5 to 2.5 mg\/kg\/day ORALLY as single dose  (50 to 75 mg\/m(2)\/day)<\/li><li><b>Crohn's disease:<\/b> adolescent patients, 1.5 mg\/kg\/day ORALLY; MAX 75 mg\/day<\/li><li><b>Non-Hodgkin's lymphoma:<\/b> optimal dose and timing yet not defined<\/li><\/ul>"},{"id":"368950-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>concomitant allopurinol:<\/b> reduce mercaptopurine dose to one-third to one-quarter of usual dose<\/li><li><b>hepatic impairment:<\/b> consider dosage reduction  or start at low end of dosage range and monitor closely for toxicity<\/li><li><b>renal impairment:<\/b> consider dosage reduction; specific guidelines are not available<\/li><li><b>myelosuppression (severe neutropenia or thrombocytopenia):<\/b> dosage reduction recommended; specific guidelines are not available<\/li><li><b>homozygous thiopurine S-methyltransferase (TPMT) enzyme deficiency:<\/b> 90% dosage reduction (10% of the standard dose) may be necessary<\/li><\/ul>"},{"id":"368950-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acute lymphoid leukemia, Maintenance therapy, as part of combination chemotherapy<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Acute myeloid leukemia<\/li><li>Chronic myeloid leukemia<\/li><li>Crohn's disease<\/li><li>Non-Hodgkin's lymphoma<\/li><li>Ulcerative colitis<\/li><\/ul>"}]},"3":{"id":"368950-s-3","title":"Contraindications\/Warnings","sub":[{"id":"368950-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to mercaptopurine or any component of the formulation<\/li><li>prior resistance to mercaptopurine or thioguanine<\/li><\/ul>"},{"id":"368950-s-3-10","title":"Precautions","mono":"<ul><li>Hematologic:<\/li><li>-- myelosuppression has been reported; monitoring recommended; reduction of dose may be necessary<\/li><li>Hepatic:<\/li><li>-- hepatotoxicity (including fatal cases), jaundice, and hepatic encephalopathy have been reported; monitoring recommended; interrupt treatment if evidence of hepatoxicity develops<\/li><li>Immunologic:<\/li><li>-- hepatosplenic T-cell lymphoma has been reported  primarily in adolescents and young adults being treated for Crohn's disease and ulcerative colitis (unapproved uses); most cases were fatal and occurred in patients receiving concomitant immunosuppressant therapies such as tumor necrosis factor (TNF) blockers and azathioprine, however there have been cases in patients receiving mercaptopurine alone; carefully assess risk\/benefit of using TNF blockers, azathioprine, and\/or mercaptopurine in this population, especially for the treatment of Crohn's disease or ulcerative colitis<\/li><li>-- immune response may be impaired; use with live virus vaccines may increase risk of infection<\/li><li>Reproductive:<\/li><li>-- avoid pregnancy in women of childbearing potential<\/li><li>Concomitant use:<\/li><li>-- concomitant use with allopurinol should be avoided<\/li><\/ul>"},{"id":"368950-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"368950-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"368950-s-4","title":"Drug Interactions","sub":[{"id":"368950-s-4-13","title":"Contraindicated","mono":"<ul><li>Febuxostat (theoretical)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><\/ul>"},{"id":"368950-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Alacepril (theoretical)<\/li><li>Alfalfa (probable)<\/li><li>Allopurinol (theoretical)<\/li><li>Azathioprine (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Benazepril (theoretical)<\/li><li>Black Cohosh (probable)<\/li><li>Captopril (established)<\/li><li>Cilazapril (theoretical)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Enalaprilat (probable)<\/li><li>Enalapril Maleate (probable)<\/li><li>Fosinopril (theoretical)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Lisinopril (theoretical)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mesalamine (probable)<\/li><li>Moexipril (theoretical)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Olsalazine (probable)<\/li><li>Oxypurinol (theoretical)<\/li><li>Pentopril (theoretical)<\/li><li>Perindopril (theoretical)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Quinapril (theoretical)<\/li><li>Ramipril (theoretical)<\/li><li>Ribavirin (probable)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Spirapril (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sulfasalazine (theoretical)<\/li><li>Trandolapril (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Warfarin (probable)<\/li><li>Yellow Fever Vaccine (established)<\/li><li>Zofenopril (theoretical)<\/li><\/ul>"},{"id":"368950-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Methotrexate (probable)<\/li><li>Phenprocoumon (probable)<\/li><\/ul>"}]},"5":{"id":"368950-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (5% to 20%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (5% to 20%), Loss of appetite (5% to 20%), Nausea (5% to 20%), Vomiting (5% to 20%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Hyperuricemia (less than 5%)<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis (less than 5%)<\/li><li><b>Hematologic:<\/b>Myelosuppression (greater than 20%)<\/li><li><b>Hepatic:<\/b>Hepatic encephalopathy, Hepatic necrosis, Hepatotoxicity (up to 6%)<\/li><li><b>Immunologic:<\/b>T-cell lymphoma, Hepatosplenic<\/li><li><b>Other:<\/b>Drug fever<\/li><\/ul>"},"6":{"id":"368950-s-6","title":"Drug Name Info","sub":{"0":{"id":"368950-s-6-17","title":"US Trade Names","mono":"<ul><li>Purinethol<\/li><li>Purixan<\/li><\/ul>"},"2":{"id":"368950-s-6-19","title":"Class","mono":"<ul><li>Antimetabolite<\/li><li>Antineoplastic Agent<\/li><\/ul>"},"3":{"id":"368950-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"368950-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"368950-s-7","title":"Mechanism Of Action","mono":"Mercaptopurine is a nucleoside metabolic inhibitor that results in cell-cycle arrest and death.<br\/>"},"8":{"id":"368950-s-8","title":"Pharmacokinetics","sub":[{"id":"368950-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability: approximately 50%<\/li><li>Tmax, oral: 2 hours<\/li><\/ul>"},{"id":"368950-s-8-24","title":"Distribution","mono":"Vd: 0.9 L\/kg <br\/>"},{"id":"368950-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic, extensive.<\/li><li>Metabolite: 6-thioguanine nucleotides, active<\/li><li>Metabolite: methylmercaptopurine, inactive<\/li><li>Metabolite: 6-thiouric acid, inactive<\/li><li>Genetic polymorphism in TPMT gene: predisposition to mercaptopurine toxicity<\/li><\/ul>"},{"id":"368950-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 46% parent drug and metabolites in the first 24 hours<\/li><li>Hemodialysis: No<\/li><\/ul>"},{"id":"368950-s-8-27","title":"Elimination Half Life","mono":"2 hours <br\/>"}]},"9":{"id":"368950-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of chemotherapy<br\/><\/li><li><b>Oral<\/b><br\/><ul><li>(suspension) shake vigorously for at least 30 seconds<\/li><li>(suspension) use within 6 weeks of opening; store between 15 and 25 degrees C (59 to 77 degrees F)<\/li><li>(suspension) if using oral syringe for multiple uses, wash with warm soapy water, rinse well, and allow to dry completely between doses<\/li><\/ul><\/li><\/ul>"},"10":{"id":"368950-s-10","title":"Monitoring","mono":"<ul><li>ANC and platelet count periodically to ensure appropriate dosing<\/li><li>improvement in clinical symptoms indicates efficacy<\/li><li>CBC  plus differential<\/li><li>thiopurine S-methyltransferase deficiency; in patients with repeated severe myelosuppression or evidence of severe bone marrow toxicity<\/li><li>serum transaminase levels, alkaline phosphatase, and bilirubin levels; weekly when beginning therapy and monthly thereafter<\/li><li>bone marrow; in patients with prolonged or repeated marrow suppression<\/li><\/ul>"},"11":{"id":"368950-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 50 MG<br\/><\/li><li><b>Purixan<\/b><br\/>Oral Suspension: 20 MG\/ML<br\/><\/li><\/ul>"},"12":{"id":"368950-s-12","title":"Toxicology","sub":[{"id":"368950-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>AZATHIOPRINE\/MERCAPTOPURINE <\/b><br\/>OVERDOSE: Nausea, vomiting, diarrhea, delayed leukopenia, increased SGOT and bilirubin, and impaired renal function can occur in overdose. ADVERSE EFFECTS: Fever, hepatitis, pancreatitis, skin rashes, and alopecia have developed Myelosuppression is the dose-limiting toxicity.<br\/><\/li><li><b>MERCAPTOPURINE<\/b><br\/>OVERDOSE: Limited overdose data available. Vomiting and severe neutropenia (nadir 11 days post ingestion) was reported after a single acute overdose in a toddler. An adult was admitted following an inadvertent overdose over a two week period with anemia, hepatic failure and seizures. She died secondary to bone marrow suppression and hepatotoxicity three days after admission.  Other overdose effects are likely to be an extension of the adverse events reported with therapy. ADVERSE EFFECTS: Mercaptopurine can cause serious dose-related bone marrow suppression, characterized by anemia, leukopenia and\/or thrombocytopenia and hepatotoxicity. Other potentially serious effects have included hyperuricemia (from lysis of leukemic cells) and intestinal ulceration. Skin hyperpigmentation, rash and diarrhea have also occurred.<br\/><\/li><\/ul>"},{"id":"368950-s-12-32","title":"Treatment","mono":"<ul><li><b>AZATHIOPRINE\/MERCAPTOPURINE <\/b><br\/><ul><li>Decontamination: Activated charcoal<\/li><li>Support: Care is symptomatic and supportive.<\/li><li>Neutropenia: Severe neutropenia: filgrastim 5 mcg\/kg\/day subcutaneously, or sargramostim 250 mcg\/m(2)\/day infused over 4 hrs.<\/li><li>Enhanced elimination procedure: Azathioprine and metabolites are hemodialyzable<\/li><li>Monitoring of patient: Serial CBC with differential due to possible delayed neutropenia, hepatic enzymes and renal function<\/li><\/ul><\/li><li><b>MERCAPTOPURINE<\/b><br\/><ul><li>Decontamination: Gastric lavage (recent ingestion), activated charcoal.<\/li><li>Support: Treatment is symptomatic and supportive. There is no known antidote for mercaptopurine therapy. Hemodialysis is not anticipated to be useful in overdose.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Myelosuppression: For severe neutropenia, administer filgrastim 5 mcg\/kg\/day subcutaneously, or sargramostim 250 mcg\/m(2)\/day infused over 4 hours. Transfusions as needed for severe thrombocytopenia or bleeding.<\/li><li>Monitoring of patient: Monitor serial CBC with differential, electrolytes, hepatic and renal function. Monitor neurologic function.<\/li><\/ul><\/li><\/ul>"},{"id":"368950-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>AZATHIOPRINE\/MERCAPTOPURINE<\/b><br\/>TOXIC DOSE: Not established. Transient neutropenia reported after azathioprine 7500 mg in an adult and 1 g (86 mg\/kg) in a toddler. No toxicity developed in an adult after 850 mg azathioprine. A toddler remained asymptomatic after up to 400 mg (26 mg\/kg) of 6-mercaptopurine. THERAPEUTIC: Azathioprine: 1 to 5 mg\/kg\/day orally. 6-mercaptopurine: 2.5 to 5 mg\/kg\/day orally.<br\/><\/li><li><b>MERCAPTOPURINE<\/b><br\/>TOXICITY:  Ingestion of 600 mg\/day for 2 weeks resulted in anemia, hepatic failure and seizures in an adult; she died three days after admission due to bone marrow suppression and hepatotoxicity. A toddler developed severe neutropenia but recovered after ingesting an estimated 86 mg\/kg (2600 mg\/m(2)). Another toddler developed no evidence of toxicity after ingesting 26 mg\/kg (785 mg\/m(2)). THERAPEUTIC: The recommended dose range for adults is 1.5 to 5 mg\/kg\/day.<br\/><\/li><\/ul>"}]},"13":{"id":"368950-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn female patients of childbearing potential to avoid pregnancy during treatment.<\/li><li>Advise patient of increased risk of malignancies and to report persistent fevers, night sweats, or significant weight loss.<\/li><li>Tell patient to avoid vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Side effects may include anorexia, diarrhea, hyperpigmentation, alopecia, or rash.<\/li><li>Advise patient to report fever, sore throat, jaundice, nausea, vomiting, signs of infection, bleeding, or symptoms of anemia.<\/li><li>Instruct patients on proper use of syringe for use with oral suspension.<\/li><li>Use the suspension within 6 weeks of first opening the bottle, then discard any remainder.<\/li><li>Patient should generally avoid concomitant administration of allopurinol.<\/li><\/ul>"}}}